Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04966325 · ClinicalTrials.gov registry record · Early Phase 1
Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects
A Early Phase 1 study, sponsored by LG Chem.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 37
- Enrollment target
NCT04966325 is a Early Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 37 participants.
The verdict
NCT04966325, a Early Phase 1 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy male and female subjects.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin 400mg
- DRUG LC350189 200mg
- DRUG LC350189 600mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2021-12-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04966325
The ClinicalTrials.gov registry entry for NCT04966325 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LG Chem, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04966325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04966325 about?
NCT04966325 is a clinical study titled "Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects". This is a Phase 1, single-center, randomized, partially double-blind, placebo- and positive controlled, 4-way crossover study to evaluate the effect of a therapeutic and a supratherapeutic dose of LC350189 on the QTcF in healthy male and female subjects.
What is the current status of trial NCT04966325?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 37 participants. The study started on 2021-09-23. Estimated completion is 2021-12-07.
What interventions are being tested in trial NCT04966325?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin 400mg (DRUG), LC350189 200mg (DRUG), LC350189 600mg (DRUG).
Who is sponsoring clinical trial NCT04966325?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.